Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment

The potential of steroid sparing from day 2 onward is reported in anthracycline-containing regimens for breast cancer treatment. We evaluated whether the reduction of dexamethasone (DEX) dose from 9.9 to 6.6 mg on day 1 is possible in anthracycline-containing treatments. Patients receiving anthracyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Yoshitaka, Takekuma, Yoh, Takeshita, Takashi, Sugawara, Mitsuru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640031/
https://www.ncbi.nlm.nih.gov/pubmed/34857855
http://dx.doi.org/10.1038/s41598-021-02765-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640031/
https://www.ncbi.nlm.nih.gov/pubmed/34857855
http://dx.doi.org/10.1038/s41598-021-02765-3

Ejemplares similares